<DOC>
	<DOCNO>NCT00002909</DOCNO>
	<brief_summary>Phase I trial study effectivenes phenylbutyrate treat adult refractory solid tumor lymphoma . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Phenylbutyrate Treating Patients With Refractory Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose oral phenylbutyrate give three time daily patient refractory solid tumor lymphoma disease progression trough plasma concentration 2-6 micromoles per liter achieve . II . Characterize pharmacokinetics oral phenylbutyrate absorption , determine whether time dependence systemic clearance rate multiple dosing . III . Seek preliminary evidence therapeutic activity phenylbutyrate administer schedule patient . IV . Correlate observe response toxic effect result bioassay tissue sample phenylbutyrate activity . OUTLINE : This dose-seeking study . All patient receive oral phenylbutyrate three time daily . Groups 4 patient receive escalate dos phenylbutyrate maximum tolerate dose ( MTD ) determine . Treatment continue disease progression unacceptable toxicity intervenes .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor lymphoma progressive refractory conventional therapy effective therapy know Priority give hormonerefractory prostate cancer melanoma No untreated CNS metastasis Head CT require absence clinical sign symptom recommend metastatic melanoma PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month WBC great 2,000/mm3 OR absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL Bilirubin le 1.5 mg/dL AST/ALT le 1.5 time normal Creatinine le 2.0 mg/dL Obstructive uropathy allow relieved nephrostomy appropriate device Left ventricular ejection fraction great 40 % MUGA normal echocardiogram No history congestive heart failure No uncontrolled hypertension ( diastolic great 110 mm Hg ) Forced expiratory volume ( 1 second ) great 1.5 L/min No active infection , include HIV viral hepatitis No active seizure disorder No clinical evidence increase intracranial pressure No baseline dementia ( minimental exam le 23 ) No autoimmune disease , include systemic lupus erythematosus , scleroderma , connective tissue illness No nonmalignant medical psychiatric problem sufficient severity limit full compliance study pose undue risk Not pregnant nursing Adequate contraception require fertile patient 2 week prior , , 3 month study Normal gastrointestinal function ability tolerate large intake oral volume require phenylbutyrate administration Patients persistent nausea moderate severe anorexia may good candidate study PRIOR CONCURRENT THERAPY : Fully recover prior therapy Prior suramin allow serum suramin level less 50 micrograms/mL entry At least 28 day since chemotherapy No prior phenylacetate , phenylbutyrate , antineoplaston therapy The following may continue study : Luteinizing hormonereleasing hormone agonist evidence tumor progression ( e.g. , rise prostatespecific antigen , new lesion bone scan ) despite therapy Adrenal steroid replacement ( need ) Dexamethasone steroid At least 46 week since flutamide evidence PSA progression require ( possible ) At least 28 day since radiotherapy At least 28 day since major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>